Patent Owner Precluded from Asserting in Litigation Claims Obtained Through Ex Parte Reexamination

Oct 21, 2019

Reading Time : 2 min

In 2014, Plaintiffs sued Defendants in district court for infringement of a patent directed to “mobile tethering” technology. In response, Defendants sought IPR, challenging the patentability of each of the claims that Plaintiffs asserted in their infringement contentions. The court then stayed the patent infringement action pending the Board’s resolution of the IPR. Ultimately, the Board found all challenged claims unpatentable except for one. Plaintiffs appealed the Board’s decision to the Federal Circuit. While their appeal was pending, Plaintiffs sought ex parte reexamination of the patent at issue in the IPR, and successfully obtained new claims through the reexamination process. With their new claims in hand, Plaintiffs sought leave from the court to amend their infringement contentions to add the newly acquired claims.

The court, applying a local rule that requires a party to show “good cause” to amend infringement contentions, denied Plaintiffs’ request. In doing so, the court explained that it had stayed the infringement action because of the possibility of “substantially streamlin[ing]” the case if the Board found unpatentable some or all of the claims at issue in the IPR. And that is exactly what happened. The IPR resulted in all but one claim surviving. The court found that allowing Plaintiffs to “re-expand the scope of the case, dramatically, by asserting what could be [numerous] claims generated in the reexamination” would render the stay “essentially pointless”—a result the court did not intend.

In analyzing whether “good cause” exists for Plaintiffs to amend their infringement contentions, the court determined that the two factors—namely, (1) whether the moving party was diligent in moving to amend its contentions, and (2) whether the non-moving party would suffer prejudice if leave to amend were granted—both weighed against allowing the amendment. Regarding diligence, the court first explained that Plaintiffs are not automatically entitled to amend their contentions simply because they obtained new claims through reexamination. The court further noted that, because Plaintiffs failed to present to the court the new infringement contentions they are seeking to add, the court cannot ascertain how the new contentions differ from the initial contentions or when any newly-accused products entered the market. The court also found that Defendants would be unduly prejudiced by the amendment because they will have to “devote extensive time and resources to litigate [numerous] new claims” after the case had already been “substantially and successfully narrowed through years of PTAB proceedings.” The court noted that “judicial economy” weighs against allowing Plaintiffs to essentially start the case over with “scores of new claims.”

Practice Tip: Because ex parte reexamination does not reset the one-year deadline for filing a petition for IPR, new claims obtained through reexamination may be immune from IPR attacks. See Apple Inc., v. IXI IP, LLC, IPR2019-00124, -00125, -00139, -00140, -00141, -00181 (PTAB June 3, 2019) (Tierney) which we covered in an earlier post in IP Newsflash. However, patent owners seeking to add claims obtained through reexamination to a district court litigation must recognize that amendment of infringement contentions is not automatic and instead carries a burden that may not be easily met.

IXI Mobile (R&D) Ltd. et al. v. Samsung Electronics Co., Ltd. et al., 4:15-cv-03752 (N.D. Cal. October 11, 2019) (Haywood S. Gilliam, Jr.)

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.